Monday, April 6, 2009

Impax Confirms Patent Challenge Relating to Renvela 800 mg Tablets

Apr 6, 2009 - Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patents listed by Genzyme Corporation in connection with its Renvela (sevelamer carbonate) 800 mg tablets.

The details can be read here.
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)